Skip to main content

Table 1 Patient information

From: Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

Patient ID Age Sex Cytogenetics CD33 (%) FLT3 (SFI)
1 46 F FLT3-ITD
NPM1 p.W288fs (Exon12)
DNMT3A p.r882C (Exon23)
PTPN11 p.G60R (Exon3)
90.5 3.03
2 45 M FLT3-ITD 95.8 2.03
3 34 F FLT3-ITD
PML-RARα
97 1.78
4 52 F FLT3-ITD
NMP1 p.W288fs
96.32 4.87
5 45 F FLT3-ITD
PML-RARα
94.1 1.40
6 46 F FLT3-WT
DNMT3A p.R882C (Exon23)
65.5 1.49
7 27 M FLT3-WT
CBFβ-MYH11
NRAS p.G12D (Exon2)
NRAS p.Q61K (Exon3)
91.2 1.94
8 26 F FLT3-WT
CBFβ-MYH11
NRAS p.Q61K (Exon3)
44 1.5
9 19 F FLT3-WT
CBFβ-MYH11
KIT p.N822K (Exon17)
NRAS p.G13D (Exon2)
66 2.65
10 34 F FLT3-WT
CBFβ-MYH11
NRAS p.Q61H (Exon3)
89.6 2
  1. F female, M male, SFI specific fluorescence indices